# A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BC

Source: https://onco.cc/trials/nct05999149/  
OnCo record `nct05999149` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of camrelizumab in triple-negative breast cancer, run by Fudan University, now recruiting.

## Summary

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) is a phase 3, randomised interventional study registered as NCT05999149 by Fudan University, with a registry enrolment figure of 424 participants, started 2023-08-20 and due to reach its primary completion in 2025-08-30. Interventions recorded: Camrelizumab Plus Chemotherapy and Famitinib; Camrelizumab Plus Chemotherapy. Conditions listed: TNBC - Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Early or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: BCTOP-T-N01
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05999149
- Phase: 3
- Setting: A Randomized, Open Label, Multicenter Phase III Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
- Sponsor: Fudan University
- Enrolled: 424

## Sources

- ClinicalTrials.gov NCT05999149: https://clinicaltrials.gov/study/NCT05999149

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05999149.json